Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Melissa Miranda

Nurse Practitioner Wesley Chapel, FL Nurse Practitioner

NPI 1235648882 CMS profile 10534528

2352 Bruce B Downs Blvd Ste 206, Wesley Chapel, FL 33544

Open in the dashboard

General payments

$15,271

810 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Melissa Miranda of Wesley Chapel, FL is reported in the CMS Open Payments database as having received $15,271 across 810 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,462 101
2024 General $3,248 133
2023 General $3,768 204
2022 General $3,807 234
2021 General $1,986 138

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Melissa Miranda
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Melissa Miranda were reported at $2,462. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Melissa Miranda Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,986 $135 $40–$426 $132
2022 $3,807 $152 $48–$470 $149
2023 $3,768 $166 $54–$529 $160
2024 $3,248 $173 $55–$556 $164
2025 $2,462 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $3,068 164 payments
  2. UCB, Inc. $1,534 68 payments
  3. Pfizer Inc. $986 57 payments
  4. Neurocrine Biosciences, Inc. $762 42 payments
  5. Teva Pharmaceuticals USA, Inc. $691 58 payments
  6. Amgen Inc. $668 49 payments
  7. Biohaven Pharmaceutical Holding Company Ltd. $584 40 payments
  8. Lundbeck LLC $531 22 payments
  9. Lilly USA, LLC $385 22 payments
  10. Jazz Pharmaceuticals Inc. $372 13 payments
  11. Other $5,688 275 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $15,271 810 payments
Products named General payments · program years 2021–2025
  1. UBRELVY $1,379 72 payments
  2. QULIPTA $1,259 60 payments
  3. NURTEC ODT Pain $966 56 payments
  4. NURTEC ODT Primary Care $809 59 payments
  5. AIMOVIG $736 59 payments
  6. ZAVZPRET $663 42 payments
  7. INGREZZA $631 33 payments
  8. Briviact $628 30 payments
  9. BOTOX $436 24 payments
  10. Nayzilam $389 20 payments
  11. Other $9,848 491 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 62 drugs

Part D claims

3,135

Median for Nurse Practitioner: 389

Drug cost

$1,274,172

Median for Nurse Practitioner: $21,885

Branded share of claims

35.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 29 $251,500
Emgality Pen Galcanezumab-Gnlm Brand 185 $150,408
Privigen Immun Glob G(Igg)/Pro/Iga 0-50 Brand 16 $131,758
Botox Onabotulinumtoxina Brand 94 $121,102
Qulipta Atogepant Brand 94 $120,445
Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 Brand 36 $93,096
Ubrelvy Ubrogepant Brand 56 $82,618
Nurtec Odt Rimegepant Sulfate Brand 67 $81,331
Aimovig Autoinjector Erenumab-Aooe Brand 71 $79,986
Neupro Rotigotine Brand 23 $32,760

The 10 drugs with the highest cost, of 62 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$61,014

Of which drugs: $35,553

Medicare patients

261

Average age 73

Services billed

7,626

173 women, 88 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 64%
Depression 44%
Ischemic heart disease 38%
Chronic kidney disease 36%
Diabetes 29%
Atrial fibrillation 26%
Alzheimer's or dementia 25%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 19 7,211 $35,552

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 34 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $339
$339 56 —
INGREZZA
  • Neurocrine Biosciences, Inc. $229
$229 29 —
BOTOX
  • AbbVie, Inc. $194
$194 94 7,211
Fintepla
  • UCB, Inc. $192
$192 — —
QULIPTA
  • AbbVie, Inc. $165
$165 94 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 34 with Patron

Records

810 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record